Perceptions, Knowledge, and Patterns of Use of “Fish Oil” Products in Cardiac Patients

Elizabeth B Hawkins; Hua Ling; Tammy L Burns; Daniel E Hilleman

doi:10.1002/j.1875-9114.2012.01219

Perceptions, Knowledge, and Patterns of Use of “Fish Oil” Products in Cardiac Patients

Elizabeth B Hawkins, Hua Ling, Tammy L Burns, Daniel E Hilleman

Department of Pharmacy Practice

Research output: Contribution to conference › Presentation

Abstract

 PURPOSE:To determine cardiac patients’ beliefs, knowledge and patterns of use of “fish oil” products (FOP).
 METHODS:Patients using a FOP admitted to a university-affiliated cardiology service were interviewed by pharmacy students or pharmacists. Patients were asked questions about their FOP including the following: indication, who recommended the product, place of purchase, active ingredient, brand, dose, and cost of product.
 RESULTS:A total of 496 patients were included. Comorbidities included coronary disease (96%), dyslipidemia (72%), hypertension (70%), and coronary revascularization (45%). Sixty percent-age indicated they were taking FOP for a specific disease indication while 40% indicated they were taking FOP for a general health indication (heart health, brain health, general health).Only 10% indicated they were taking a FOP specifically for a lipid disorder. Only 9% (n=45) of patients were told to take a FOP by their physician. Only 22 were given prescriptions for Lovaza®. Nine of these 22 patients were actually filling their Lovaza®prescriptions. Seventy-five percentage of patients could not identify the active ingredient in their FOP. A total of 107 patients accurately identified the active ingredient in their FOP, but only 23 knew the dose they were taking. Seventy-three percentage of patients indicated they purchased the same brand of FOP each time they purchased their FOP. Seventeen percentage of patients purchased their FOP in a pharmacy. Ninety-eight percentage of patients paid less than $25 per month for their FOP while 47%spent less than $15 per month. Only 2% of patients paid more than $25 per month and all were receiving Lovaza®.CONCLUSION:The results of this study indicate that the vast majority of patients are under-educated concerning their FOP.Few patients (10%) are actually taking FOP for lipid disorders,while only 9% were told to take FOP by their physicians. Pharmacists should play a greater role in educating patients about the use of FOP.

Original language	American English
DOIs	https://doi.org/10.1002/j.1875-9114.2012.01219
State	Published - 2012
Event	ACCP 2012 Annual Meeting - Hollywood, FL Duration: Jan 1 2012 → …

Conference

Conference	ACCP 2012 Annual Meeting
Period	1/1/12 → …

Disciplines

Medicine and Health Sciences
Pharmacy and Pharmaceutical Sciences

Access to Document

10.1002/j.1875-9114.2012.01219License: Unspecified

Cite this

@conference{161171b451314b4b9cffc800574aab46,

title = "Perceptions, Knowledge, and Patterns of Use of “Fish Oil” Products in Cardiac Patients",

abstract = " PURPOSE:To determine cardiac patients{\textquoteright} beliefs, knowledge and patterns of use of “fish oil” products (FOP). METHODS:Patients using a FOP admitted to a university-affiliated cardiology service were interviewed by pharmacy students or pharmacists. Patients were asked questions about their FOP including the following: indication, who recommended the product, place of purchase, active ingredient, brand, dose, and cost of product. RESULTS:A total of 496 patients were included. Comorbidities included coronary disease (96%), dyslipidemia (72%), hypertension (70%), and coronary revascularization (45%). Sixty percent-age indicated they were taking FOP for a specific disease indication while 40% indicated they were taking FOP for a general health indication (heart health, brain health, general health).Only 10% indicated they were taking a FOP specifically for a lipid disorder. Only 9% (n=45) of patients were told to take a FOP by their physician. Only 22 were given prescriptions for Lovaza{\textregistered}. Nine of these 22 patients were actually filling their Lovaza{\textregistered}prescriptions. Seventy-five percentage of patients could not identify the active ingredient in their FOP. A total of 107 patients accurately identified the active ingredient in their FOP, but only 23 knew the dose they were taking. Seventy-three percentage of patients indicated they purchased the same brand of FOP each time they purchased their FOP. Seventeen percentage of patients purchased their FOP in a pharmacy. Ninety-eight percentage of patients paid less than $25 per month for their FOP while 47%spent less than $15 per month. Only 2% of patients paid more than $25 per month and all were receiving Lovaza{\textregistered}.CONCLUSION:The results of this study indicate that the vast majority of patients are under-educated concerning their FOP.Few patients (10%) are actually taking FOP for lipid disorders,while only 9% were told to take FOP by their physicians. Pharmacists should play a greater role in educating patients about the use of FOP.",

author = "Hawkins, {Elizabeth B} and Hua Ling and Burns, {Tammy L} and Hilleman, {Daniel E}",

year = "2012",

doi = "10.1002/j.1875-9114.2012.01219",

language = "American English",

note = "ACCP 2012 Annual Meeting ; Conference date: 01-01-2012",

}

TY - CONF

T1 - Perceptions, Knowledge, and Patterns of Use of “Fish Oil” Products in Cardiac Patients

AU - Hawkins, Elizabeth B

AU - Ling, Hua

AU - Burns, Tammy L

AU - Hilleman, Daniel E

PY - 2012

Y1 - 2012

N2 - PURPOSE:To determine cardiac patients’ beliefs, knowledge and patterns of use of “fish oil” products (FOP). METHODS:Patients using a FOP admitted to a university-affiliated cardiology service were interviewed by pharmacy students or pharmacists. Patients were asked questions about their FOP including the following: indication, who recommended the product, place of purchase, active ingredient, brand, dose, and cost of product. RESULTS:A total of 496 patients were included. Comorbidities included coronary disease (96%), dyslipidemia (72%), hypertension (70%), and coronary revascularization (45%). Sixty percent-age indicated they were taking FOP for a specific disease indication while 40% indicated they were taking FOP for a general health indication (heart health, brain health, general health).Only 10% indicated they were taking a FOP specifically for a lipid disorder. Only 9% (n=45) of patients were told to take a FOP by their physician. Only 22 were given prescriptions for Lovaza®. Nine of these 22 patients were actually filling their Lovaza®prescriptions. Seventy-five percentage of patients could not identify the active ingredient in their FOP. A total of 107 patients accurately identified the active ingredient in their FOP, but only 23 knew the dose they were taking. Seventy-three percentage of patients indicated they purchased the same brand of FOP each time they purchased their FOP. Seventeen percentage of patients purchased their FOP in a pharmacy. Ninety-eight percentage of patients paid less than $25 per month for their FOP while 47%spent less than $15 per month. Only 2% of patients paid more than $25 per month and all were receiving Lovaza®.CONCLUSION:The results of this study indicate that the vast majority of patients are under-educated concerning their FOP.Few patients (10%) are actually taking FOP for lipid disorders,while only 9% were told to take FOP by their physicians. Pharmacists should play a greater role in educating patients about the use of FOP.

AB - PURPOSE:To determine cardiac patients’ beliefs, knowledge and patterns of use of “fish oil” products (FOP). METHODS:Patients using a FOP admitted to a university-affiliated cardiology service were interviewed by pharmacy students or pharmacists. Patients were asked questions about their FOP including the following: indication, who recommended the product, place of purchase, active ingredient, brand, dose, and cost of product. RESULTS:A total of 496 patients were included. Comorbidities included coronary disease (96%), dyslipidemia (72%), hypertension (70%), and coronary revascularization (45%). Sixty percent-age indicated they were taking FOP for a specific disease indication while 40% indicated they were taking FOP for a general health indication (heart health, brain health, general health).Only 10% indicated they were taking a FOP specifically for a lipid disorder. Only 9% (n=45) of patients were told to take a FOP by their physician. Only 22 were given prescriptions for Lovaza®. Nine of these 22 patients were actually filling their Lovaza®prescriptions. Seventy-five percentage of patients could not identify the active ingredient in their FOP. A total of 107 patients accurately identified the active ingredient in their FOP, but only 23 knew the dose they were taking. Seventy-three percentage of patients indicated they purchased the same brand of FOP each time they purchased their FOP. Seventeen percentage of patients purchased their FOP in a pharmacy. Ninety-eight percentage of patients paid less than $25 per month for their FOP while 47%spent less than $15 per month. Only 2% of patients paid more than $25 per month and all were receiving Lovaza®.CONCLUSION:The results of this study indicate that the vast majority of patients are under-educated concerning their FOP.Few patients (10%) are actually taking FOP for lipid disorders,while only 9% were told to take FOP by their physicians. Pharmacists should play a greater role in educating patients about the use of FOP.

U2 - 10.1002/j.1875-9114.2012.01219

DO - 10.1002/j.1875-9114.2012.01219

M3 - Presentation

T2 - ACCP 2012 Annual Meeting

Y2 - 1 January 2012

ER -